Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 8/20 | 0.41 |
| ▸ | KLK7 | P49862 | 4/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12011377 | 0.91 | HTR6 (0.43) | KDM4EUBE2NL3MBTL1HTR6KLK7 | |
| SCHEMBL1888127 | 0.90 | KDM4E (0.41) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL1894122 | 0.89 | HTR6 (0.55) | HTR6 | |
| SCHEMBL30088058 | 0.88 | HTR6 (0.45) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL10182014 | 0.88 | KDM4E (0.56) | KDM4EUBE2NL3MBTL1HTR6KLK7 | |
| SCHEMBL29414046 | 0.88 | KDM4E (0.56) | KDM4EUBE2NL3MBTL1HTR6KLK7 | |
| SCHEMBL9904700 | 0.85 | L3MBTL1 (0.41) | KDM4EUBE2NL3MBTL1HTR6KLK7 | |
| SCHEMBL12614952 | 0.85 | CYP2C9 (0.43) | KDM4EUBE2NHTR6ALOX5 | |
| SCHEMBL1892254 | 0.84 | HTR6 (0.39) | KDM4EUBE2NL3MBTL1HTR6KLK7 | |
| SCHEMBL1887673 | 0.84 | HTR6 (0.52) | KDM4EUBE2NL3MBTL1HTR6KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247592-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-7939531-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2247592-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106442-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | KDM4E 598/4885UBE2N 1819/4885L3MBTL1 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.